A radical, potentially game-changing technology that threatens to destroy the trillion-dollar, “green energy” grift of the elites. And yet, while it threatens their wealth and power, it could be transformational for both the U.S. economy and your wealth.

One company holds a near-total monopoly on it.

Cyrus Harmon Biography and Net Worth

CTO of Olema Pharmaceuticals

Dr. Harmon co-founded Olema Oncology and has served as Chief Technology Officer since September 2020 and a member of the Board of Directors since August 2006. He served as President and Chief Executive Officer from March 2007 to September 2020. Before Olema, he was Vice President of Computational Genomics and General Manager at Affymetrix, Inc., which was acquired by Thermo Fisher Scientific. He founded and served as Chief Executive Officer of Neomorphic, Inc., which was acquired by Affymetrix, Inc. Dr. Harmon received a B.A. and Ph.D. in molecular and cell biology from the University of California, Berkeley.

What is Cyrus Harmon's net worth?: The estimated net worth of Cyrus Harmon is at least $7.93 million as of May 6th, 2024. Dr. Harmon owns 806,283 shares of Olema Pharmaceuticals stock worth more than $7,933,825 as of May 19th. This net worth estimate does not reflect any other investments that Dr. Harmon may own. Learn More about Cyrus Harmon's net worth.
How do I contact Cyrus Harmon?: The corporate mailing address for Dr. Harmon and other Olema Pharmaceuticals executives is 512 2ND STREET 4TH FLOOR, SAN FRANCISCO CA, 94107. Olema Pharmaceuticals can also be reached via phone at 650-243-5555 and via email at [email protected]. Learn More on Cyrus Harmon's contact information.
Has Cyrus Harmon been buying or selling shares of Olema Pharmaceuticals?: During the past quarter, Cyrus Harmon has sold $197,250.00 in Olema Pharmaceuticals stock. Most recently, Cyrus Harmon sold 5,000 shares of the business's stock in a transaction on Monday, May 6th. The shares were sold at an average price of $10.92, for a transaction totalling $54,600.00. Following the completion of the sale, the director now directly owns 806,283 shares of the company's stock, valued at $8,804,610.36. Learn More on Cyrus Harmon's trading history.
Who are Olema Pharmaceuticals' active insiders?: Olema Pharmaceuticals' insider roster includes Sean Bohen (CEO), Cyrus Harmon (CTO), and Kinney Horn (Insider). Learn More on Olema Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Olema Pharmaceuticals?: During the last twelve months, Olema Pharmaceuticals insiders bought shares 3 times. They purchased a total of 1,737,802 shares worth more than $17,849,606.18. During the last twelve months, insiders at the sold shares 20 times. They sold a total of 278,355 shares worth more than $3,361,842.47. The most recent insider tranaction occured on May, 6th when Director Cyrus Harmon sold 5,000 shares worth more than $54,600.00. Insiders at Olema Pharmaceuticals own 23.5% of the company. Learn More about insider trades at Olema Pharmaceuticals.
Information on this page was last updated on 5/6/2024.

Cyrus Harmon Insider Trading History at Olema Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
5/6/2024	Sell	5,000	$10.92	$54,600.00	806,283
4/30/2024	Sell	15,000	$9.51	$142,650.00	811,283
3/28/2024	Sell	20,000	$10.97	$219,400.00	826,283
2/29/2024	Sell	25,000	$12.41	$310,250.00	846,283
1/31/2024	Sell	25,000	$12.23	$305,750.00	876,283
11/30/2023	Sell	25,000	$12.57	$314,250.00	926,283
11/21/2023	Sell	4,192	$14.86	$62,293.12	955,272
11/2/2023	Sell	5,000	$15.64	$78,200.00	943,714
10/31/2023	Sell	25,000	$12.05	$301,250.00	948,714
9/29/2023	Sell	25,000	$12.41	$310,250.00	973,714
9/5/2023	Sell	10,000	$11.62	$116,200.00	998,714
8/31/2023	Sell	15,000	$9.36	$140,400.00	1,008,714
6/8/2023	Sell	10,000	$6.30	$63,000.00	1,038,714
6/5/2023	Sell	5,000	$6.04	$30,200.00	1,053,714
11/29/2021	Sell	400	$24.76	$9,904.00
10/19/2021	Sell	12,000	$27.98	$335,760.00
9/20/2021	Sell	12,000	$26.30	$315,600.00
8/19/2021	Sell	12,000	$24.97	$299,640.00	1,075,546
7/20/2021	Sell	4,123	$25.63	$105,672.49
6/18/2021	Sell	12,000	$24.80	$297,600.00	1,102,136

Cyrus Harmon Buying and Selling Activity at Olema Pharmaceuticals

Olema Pharmaceuticals Company Overview

Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; and OP-1250 combine with CDK4/6 inhibitors palbociclib, ribociclib, and alpelisib in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer, as well as develops OPERA-01 for the of ER+/HER2- advanced or metastatic breast cancer. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.

Today's Range

Now: $9.84

$9.61

$10.08

50 Day Range

MA: $10.76

$9.22

$13.00

2 Week Range

Now: $9.84

$5.02

$17.79

Volume

547,900 shs

Average Volume

785,210 shs

Market Capitalization

$550.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.1

The most important AI company you've never heard of

From Manward Press | Ad

Because this small company solves the BIGGEST problem with Nvidia's AI chips. Already, Amazon, Microsoft, Google and others are lining up to get this company's products.

Get the full story on this secret AI company poised for massive growth